Danaher Corporation

Danaher Corporation (DHR) Market Cap

Danaher Corporation has a market capitalization of $137.82B.

Financials based on reported quarter end 2025-12-31

Price: $194.75

▲ 0.97 (0.50%)

Market Cap: 137.82B

NYSE · time unavailable

CEO: Rainer Blair

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1978-12-29

Website: https://www.danaher.com

Danaher Corporation (DHR) - Company Information

Market Cap: 137.82B · Sector: Healthcare

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Analyst Sentiment

82%
Strong Buy

Based on 25 ratings

Analyst 1Y Forecast: $246.50

Average target (based on 7 sources)

Consensus Price Target

Low

$205

Median

$254

High

$270

Average

$249

Potential Upside: 28.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 Danaher Corporation (DHR) — Investment Overview

🧩 Business Model Overview

Danaher Corporation operates as a diversified life sciences and diagnostics conglomerate, supporting a broad spectrum of healthcare, research, and applied sciences organizations. The company’s core offerings span sophisticated instrumentation, consumable reagents, automation platforms, digital solutions, and related technical services. Danaher’s primary customers include biopharmaceutical companies, academic and clinical laboratories, research institutions, and healthcare providers worldwide. The company’s operating domains are anchored in the Life Sciences, Diagnostics, and Biotechnology Tool sectors, addressing critical workflows in scientific discovery, drug development, diagnostic testing, and laboratory automation.

💰 Revenue Model & Ecosystem

Danaher’s revenue model is multi-faceted, drawing from both recurring and transactional streams. Significant sales come from durable instrumentation and equipment, which are further supported by essential recurring sales of consumables such as reagents, test kits, and labware. The company leverages service contracts, software subscriptions, and digital analytics tools to create ongoing customer engagement and incremental revenue. Its enterprise-focused ecosystem delivers integrated hardware-software solutions central to laboratory operations, while after-market services—such as equipment maintenance, compliance validation, and training—reinforce long-term customer relationships.

🧠 Competitive Advantages

  • Brand strength: Danaher’s portfolio includes globally recognized brands synonymous with reliability and innovation, fostering customer trust in regulated, precision-driven markets.
  • Switching costs: Instrument platforms are deeply embedded within customers’ workflows, making replacement costly and complex while creating customer inertia.
  • Ecosystem stickiness: Interconnected product suites and data integration services enhance the value proposition, encouraging customers to standardize workflows around Danaher solutions.
  • Scale + supply chain leverage: Broad operational scale and optimized global sourcing drive cost efficiency, support R&D investment, and enable reliable fulfillment in demanding markets.

🚀 Growth Drivers Ahead

Long-term growth is shaped by several secular and strategic drivers. Rising global investment in pharmaceutical R&D and biologic drug development increases demand for Danaher’s life science and bioprocessing tools. Expansion in molecular and precision diagnostics addresses the shift toward personalized medicine and higher test volumes in clinical settings. Strategic acquisitions continue to broaden Danaher’s portfolio and open new end-markets. Digitalization of laboratory workflows and sustained demand for laboratory automation further underpin growth. Additionally, emerging markets present long runway for increased healthcare infrastructure investment and adoption of advanced diagnostics.

⚠ Risk Factors to Monitor

Key risks include intensifying competition from global conglomerates and nimble, innovative specialists in both instrumentation and consumables. Regulatory changes in healthcare, bioprocessing, or laboratory practices may create compliance hurdles or shift demand patterns. Margin pressure can arise from cost inflation, pricing pressure, or integration challenges following acquisitions. Disruption risk from technological advances, new diagnostic modalities, or shifts towards alternative workstreams may impact legacy business lines if not effectively managed.

📊 Valuation Perspective

Danaher typically commands a valuation premium relative to industry peers, reflecting its diversified business mix, emphasis on recurring revenue, and established track record of disciplined capital allocation. Market participants often assess Danaher favorably on the basis of its innovative capability, resilient cash flow generation, and ability to deliver consistent operational improvement, especially amid economic uncertainty. Its leadership in high-growth life sciences and diagnostics domains underpins investor confidence in sustained long-term performance.

🔍 Investment Takeaway

Danaher offers a compelling blend of stability, innovation, and strategic growth in essential scientific and healthcare end-markets. The bullish case rests on its scalable operating model, culture of continuous improvement, and ability to expand through both organic innovation and acquisition. Bearish considerations center on competitive intensity, potential regulatory headwinds, integration risk, and the company’s premium market expectations. Overall, Danaher stands out as a high-quality operator, but prudent investors should continually assess its ability to sustain competitive advantages and execute on emerging growth opportunities in a rapidly evolving industry environment.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

Related Companies in Healthcare

STRYKER CORP (SYK)

Healthcare

$131.38B

Mkt Cap

BRISTOL MYERS SQUIBB (BMY)

Healthcare

$122.85B

Mkt Cap

PFIZER INC (PFE)

Healthcare

$156.77B

Mkt Cap

VERTEX PHARMACEUTICALS INC (VRTX)

Healthcare

$112.22B

Mkt Cap

MEDTRONIC PLC (MDT)

Healthcare

$110.66B

Mkt Cap

HCA HEALTHCARE INC (HCA)

Healthcare

$109.13B

Mkt Cap

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Danaher Corporation reported a revenue of $6.84 billion for the quarter ending December 31, 2025, with a net income of $1.197 billion, translating to an EPS of $1.69. The net margin was approximately 17.5%, and the company generated a free cash flow of $1.75 billion. Compared to the previous year's figures, this represents stable revenue growth and improved profitability metrics. Danaher's robust operating cash flow of $2.12 billion compares favorably with its capital expenditures of $371 million, underscoring strong cash flow management. The company's balance sheet reflects total assets of $83.46 billion against total liabilities of $30.93 billion, resulting in equity of $52.54 billion. Danaher's net debt stands at $13.8 billion, indicating a prudent approach to leverage. The company's consistent dividend payout of $0.32 per share signals a commitment to returning value to shareholders. Analyst sentiment remains positive, with price targets averaging at $252.33. The valuation assessment, given the current market conditions, aligns with Danaher's strategic financial standing, though macroeconomic conditions could impact investor sentiments further."

Revenue Growth

Positive

The revenue of $6.84 billion indicates stable growth with ongoing contributions from diverse business segments.

Profitability

Good

Net income and EPS have grown, resulting in a solid net margin of 17.5% reflecting effective cost management.

Cash Flow Quality

Good

Strong free cash flow of $1.75 billion, backed by healthy operations and manageable capex, ensures liquidity.

Leverage & Balance Sheet

Positive

With a net debt to equity ratio suggesting a conservative leverage approach, the company has maintained a solid financial position.

Shareholder Returns

Good

Regular dividends and buybacks indicate a solid commitment to enhancing shareholder value.

Analyst Sentiment & Valuation

Good

Analyst price targets suggest an optimistic outlook, supported by appropriate valuation given recent performance.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Danaher delivered a solid Q4 and FY25 with modest core growth, stronger-than-expected bioprocessing, and improving diagnostics momentum. Margins dipped year over year, but EPS and cash flow outperformed, underscoring strong execution and disciplined cost management. Management guided to 3%–6% core growth and higher EPS in 2026, with bioprocessing remaining a key driver, diagnostics accelerating as China headwinds moderate, and life sciences improving modestly. While funding constraints, China policy pressures, and uneven equipment orders persist, the tone was constructive, supported by a robust innovation pipeline, resilient consumables, and strong cash generation.

Growth

  • Q4 core revenue +2.5%; FY25 core revenue +2%
  • Biotechnology segment core revenue +6%; Bioprocessing high single-digit growth (consumables HSD; equipment MSD; equipment returned to growth)
  • Life Sciences segment core revenue +0.5%; instruments ~flat; clinical/applied markets healthy
  • Diagnostics segment core revenue +2%; Clinical Diagnostics mid-single-digit growth; Leica Biosystems and Radiometer ~+10%; Beckman Coulter Diagnostics MSD globally
  • Cepheid non-respiratory menu grew low double digits; sexual health ~+30%; hospital-acquired infections mid-teens
  • New product revenue ~+25% y/y
  • Geography: Developed markets low single-digit (NA ~flat; Western Europe MSD); High-growth markets MSD; China LSD decline

Business Development

  • Cytiva launched >20 biologics workflow products, including AcelRx X bioreactors (500L, 2,000L) and new protein A resins (MabSelect SURE 70, MabSelect PRISMA X)
  • SCIEX launched Xenotop 8600 mass spectrometer (up to 30x sensitivity)
  • Beckman Coulter Life Sciences added MosaiQ spectral detection to CytoFLEX
  • Beckman Coulter Diagnostics expanded DXi9000 assay menu, including first-to-market automated high-throughput BD tau RUO immunoassay
  • Cepheid received FDA clearance for Xpert GI panel (11-pathogen multiplex) using 10-color multiplexing; continued multiplex strategy (e.g., 4-in-1 respiratory, MVP in women’s health)
  • Improving bioprocessing equipment order trends (third consecutive quarter of sequential growth); strength in short-cycle line additions/brownfields; U.S. reshoring greenfields potential upside
  • Abcam showing sequential improvement via pharma and recombinant proteins initiatives

Financials

  • Q4 sales $6.8B; adjusted gross margin 58.2%; adjusted operating margin 28.3% (down 130 bps y/y); adjusted EPS $2.23 (+4% y/y); Q4 free cash flow $1.8B
  • FY25 sales $24.6B; adjusted operating margin 28.2%; adjusted diluted EPS $7.80 (+4.5% y/y)
  • FY25 free cash flow $5.3B; FCF-to-net income conversion ~145% (34th consecutive year >100%)
  • Bioprocessing: backlog and order trajectory support 2026 equipment revenue ~flat; consumables to lead growth

Capital & Funding

  • Strong balance sheet cited to support long-term value creation
  • Robust FY25 free cash flow generation ($5.3B) with ~145% FCF-to-NI conversion
  • Ongoing productivity and innovation investments; cost-savings initiatives executed
  • No specific updates on M&A, buybacks, or dividends in the call

Operations & Strategy

  • Leveraging the Danaher Business System to offset cost pressures, drive productivity, and support innovation
  • Focus on high recurring revenue models across Life Sciences and Diagnostics
  • Expanding Cepheid installed base and menu; entering new care settings
  • Positioned to capture U.S. bioprocessing reshoring and brownfield expansion demand
  • Consumables-led growth strategy in bioprocessing; equipment recovery supported by backlog
  • Accelerated innovation cadence to help customers lower costs and improve outcomes

Market & Outlook

  • End markets stable q/q: robust global mAb production; modestly more favorable capex; pharma R&D recovering; biotech stable; academic/government muted but stable; clinical/applied healthy
  • Geography: North America ~flat; Western Europe MSD; high-growth markets MSD; China LSD decline with VBP headwinds expected to moderate through 2026
  • 2026 guidance: core revenue +3% to +6%; adjusted diluted EPS $8.35–$8.50
  • Q1 2026: core revenue up low single digits; adjusted operating margin ~28.5%
  • 2026 Bioprocessing expected high single-digit growth; consumables lead; equipment ~flat
  • Diagnostics growth to accelerate in 2026 as China policy headwinds abate; Cepheid respiratory revenue expected ~$1.8B (normal season/testing protocols)
  • Long-term view: high single-digit core growth potential with strong margin/FCF profile; biologics demand robust (biologics revenues surpassed small molecules in 2025; projected >2/3 of top 100 drugs by 2030)

Risks Or Headwinds

  • Academic and government funding constraints; continued softness in early-stage biotech
  • China pressures, including volume-based procurement and LSD demand decline
  • Lower plasmid and mRNA demand from two large customers
  • Bioprocessing equipment orders remain below historical levels; growth led by short-cycle projects
  • Tariff-related cost pressures; macro/geopolitical/policy uncertainty
  • Respiratory testing volumes dependent on seasonal patterns and customer protocols

Sentiment: MIXED

Note: This summary was synthesized by AI from the DHR Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (DHR)

© 2026 Stock Market Info — Danaher Corporation (DHR) Financial Profile